Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012;224(2):134-9.
doi: 10.1159/000338202. Epub 2012 May 3.

Treatment of toxic epidermal necrolysis with the combination of infliximab and high-dose intravenous immunoglobulin

Georgios Gaitanis  1 , Panagiota Spyridonos, Konstantinos Patmanidis, Vasilios Koulouras, Georgios Nakos, Margaret Tzaphlidou, Ioannis D Bassukas
Affiliations
Review

Treatment of toxic epidermal necrolysis with the combination of infliximab and high-dose intravenous immunoglobulin

Georgios Gaitanis et al. Dermatology. 2012.

Abstract

Background: Therapeutic evidence for toxic epidermal necrolysis (TEN) is indicative for high-dose intravenous immunoglobulin yet inconclusive for corticosteroids.

Objective: To describe the combination of corticosteroids, infliximab and a high-dose intravenous immunoglobulin course for TEN.

Patients and methods: In three patients (SCORTEN survival probabilities: 41.7%, 64.2%, 41.7%) disease control was evaluated by (a) employing quantitative image analysis to measure progression of skin detachment and (b) patients' outcome (complete re-epithelization). Published cases of TEN treatments with infliximab were retrieved from PubMed.

Results: Within 48 h skin disease progression was arrested in all patients. Two patients were discharged after 3 weeks without any sequels from skin or conjunctivae. One patient passed away on the ninth day, however with noticeably improved skin (mortality rate: 33% observed vs. 50% expected). A PubMed search retrieved five TEN patients treated successfully with infliximab.

Conclusion: The described combination presents a feasible therapeutic alternative for TEN that warrants further evaluation.

PubMed Disclaimer

LinkOut - more resources